Which test should be done every week for a patient who is taking Clozapine?

NORCET 3 - 2022 (Shift-2)

Pharmacology

Easy

Appeared in: NORCET 3 - 2022 (Shift-2)

Explanation

Clozapine is an atypical antipsychotic medication that carries a significant risk of causing agranulocytosis, a dangerous and potentially fatal decrease in white blood cells, specifically neutrophils.
Due to this risk, strict blood monitoring is a mandatory requirement for all patients receiving this medication.
A Complete Blood Count (CBC) with a differential is performed to measure the Absolute Neutrophil Count (ANC).
The standard protocol requires this test to be done weekly for the first six months of therapy, which is the period of highest risk.

Option B: The Erythrocyte Sedimentation Rate (ESR) is a non-specific marker of inflammation in the body. It is not used to monitor for the specific, life-threatening hematological side effects of Clozapine.
Option C: Blood Urea Nitrogen (BUN) is a test used to evaluate kidney function. While kidney function is important for drug clearance, it is not the primary, high-frequency monitoring parameter for Clozapine's most critical adverse effect.
Option D: While Clozapine can cause metabolic syndrome, including hyperglycemia (high blood sugar), weekly monitoring is not the standard protocol. The risk of agranulocytosis is more acute and requires more frequent surveillance.

Visual 1: Flowchart: Clozapine Blood Monitoring Schedule. This visual would clearly map out the required frequency of CBC tests over time (weekly for 6 months, bi-weekly for the next 6 months, and monthly thereafter), helping to reinforce the strict protocol.
Visual 2: Infographic: Signs of Agranulocytosis. This would list key symptoms for patient education, such as fever, sore throat, chills, and weakness, emphasizing the need to report them immediately.

Clinical Relevance

Nursing practice connection: Use the key finding related to Pharmacological Monitoring for Clozapine to guide bedside assessment, documentation, and the next nursing action.
A core nursing responsibility is enforcing the "No blood, no drug" policy. The pharmacy will not dispense Clozapine without a current and acceptable CBC result.
Nurses must educate patients and their families about the importance of adhering to the blood test schedule and recognizing the early signs of infection (e.g., fever, sore throat, fatigue).
What if? A patient on weekly Clozapine monitoring calls the clinic reporting a fever and sore throat, but their next blood test is not for three days. The nurse must instruct the patient to go to an emergency department or clinic immediately for a stat CBC and medical evaluation, and to hold their next dose of Clozapine until advised by the physician.

How to Approach the Question

First, identify the key medication in the question: 'Clozapine'.
Recall the most critical, life-threatening side effect associated with this specific drug. For Clozapine, this is agranulocytosis.
Connect the side effect to the necessary monitoring test. Agranulocytosis is a disorder of the white blood cells.
Evaluate the options. A Complete Blood Count (CBC) is the standard test to assess white blood cells, red blood cells, and platelets.
Eliminate the other options by considering their primary purpose: ESR (inflammation), BUN (kidney function), and Sugar profile (metabolic/glucose). None of these directly monitor for the acute hematological risk of Clozapine.

Concept Tested & Keywords

Q7QvvRKIHF5wyWkhDp35y